NO861580L - Fremgangsmaate for fremstilling av celleadhesjonsinhibitorer. - Google Patents

Fremgangsmaate for fremstilling av celleadhesjonsinhibitorer.

Info

Publication number: NO861580L
Authority: NO; Norway
Prior art keywords: antiadhesins; glycoproteins; glycolipids; antiadhesin; treatment
Prior art date: 1985-04-23

Application number

NO861580A

Other languages

English (en)

Norwegian (no)

Inventor

Raymond Julien

Michele Mouricout

Original Assignee

Limousin Inst Bio

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1985-04-23

Filing date

1986-04-22

Publication date

1986-10-24

1986-04-22 Application filed by Limousin Inst Bio filed Critical Limousin Inst Bio

1986-10-24 Publication of NO861580L publication Critical patent/NO861580L/no

Links

238000000034 method Methods 0.000 title claims abstract description 43
230000021164 cell adhesion Effects 0.000 title claims abstract description 6
239000003112 inhibitor Substances 0.000 title claims abstract description 6
238000002360 preparation method Methods 0.000 title abstract description 7
229930186217 Glycolipid Natural products 0.000 claims abstract description 18
108090000288 Glycoproteins Proteins 0.000 claims abstract description 18
102000003886 Glycoproteins Human genes 0.000 claims abstract description 18
108010015899 Glycopeptides Proteins 0.000 claims abstract description 10
102000002068 Glycopeptides Human genes 0.000 claims abstract description 10
239000000758 substrate Substances 0.000 claims abstract description 8
239000007788 liquid Substances 0.000 claims abstract description 7
230000008569 process Effects 0.000 claims abstract description 6
230000009089 cytolysis Effects 0.000 claims abstract description 4
239000007787 solid Substances 0.000 claims abstract description 4
238000011282 treatment Methods 0.000 claims description 24
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 12
239000000126 substance Substances 0.000 claims description 11
150000002632 lipids Chemical group 0.000 claims description 9
239000000203 mixture Substances 0.000 claims description 9
150000002482 oligosaccharides Chemical class 0.000 claims description 8
102000004169 proteins and genes Human genes 0.000 claims description 8
108090000623 proteins and genes Proteins 0.000 claims description 8
238000004519 manufacturing process Methods 0.000 claims description 7
230000017854 proteolysis Effects 0.000 claims description 7
230000009471 action Effects 0.000 claims description 5
229920001542 oligosaccharide Polymers 0.000 claims description 5
238000010438 heat treatment Methods 0.000 claims description 4
238000000926 separation method Methods 0.000 claims description 4
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 3
108091005804 Peptidases Proteins 0.000 claims description 3
239000004365 Protease Substances 0.000 claims description 3
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims description 3
108090001109 Thermolysin Proteins 0.000 claims description 3
238000005852 acetolysis reaction Methods 0.000 claims description 3
238000005904 alkaline hydrolysis reaction Methods 0.000 claims description 3
239000008103 glucose Substances 0.000 claims description 3
238000006698 hydrazinolysis reaction Methods 0.000 claims description 3
BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 claims description 2
WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims description 2
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
229910001424 calcium ion Inorganic materials 0.000 claims description 2
229930182830 galactose Natural products 0.000 claims description 2
229960005480 sodium caprylate Drugs 0.000 claims description 2
BYKRNSHANADUFY-UHFFFAOYSA-M sodium octanoate Chemical compound [Na+].CCCCCCCC([O-])=O BYKRNSHANADUFY-UHFFFAOYSA-M 0.000 claims description 2
239000002778 food additive Substances 0.000 claims 1
235000013373 food additive Nutrition 0.000 claims 1
235000015097 nutrients Nutrition 0.000 claims 1
239000003960 organic solvent Substances 0.000 claims 1
125000003473 lipid group Chemical group 0.000 abstract 1
210000004027 cell Anatomy 0.000 description 43
241001465754 Metazoa Species 0.000 description 19
239000002609 medium Substances 0.000 description 18
244000005700 microbiome Species 0.000 description 18
241000894006 Bacteria Species 0.000 description 16
239000003814 drug Substances 0.000 description 15
241000588724 Escherichia coli Species 0.000 description 14
244000309466 calf Species 0.000 description 14
238000012360 testing method Methods 0.000 description 14
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 12
229940079593 drug Drugs 0.000 description 11
208000015181 infectious disease Diseases 0.000 description 11
230000005764 inhibitory process Effects 0.000 description 11
210000003097 mucus Anatomy 0.000 description 11
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
239000000284 extract Substances 0.000 description 8
238000006460 hydrolysis reaction Methods 0.000 description 8
241000196324 Embryophyta Species 0.000 description 7
238000005119 centrifugation Methods 0.000 description 7
230000000694 effects Effects 0.000 description 7
230000007062 hydrolysis Effects 0.000 description 7
206010012735 Diarrhoea Diseases 0.000 description 6
241000699670 Mus sp. Species 0.000 description 6
230000000968 intestinal effect Effects 0.000 description 6
241000894007 species Species 0.000 description 6
230000001580 bacterial effect Effects 0.000 description 5
238000000605 extraction Methods 0.000 description 5
230000002401 inhibitory effect Effects 0.000 description 5
239000012528 membrane Substances 0.000 description 5
238000007790 scraping Methods 0.000 description 5
230000028327 secretion Effects 0.000 description 5
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
230000001464 adherent effect Effects 0.000 description 4
210000004369 blood Anatomy 0.000 description 4
239000008280 blood Substances 0.000 description 4
239000000969 carrier Substances 0.000 description 4
239000000470 constituent Substances 0.000 description 4
238000002474 experimental method Methods 0.000 description 4
238000001914 filtration Methods 0.000 description 4
238000011081 inoculation Methods 0.000 description 4
230000003993 interaction Effects 0.000 description 4
210000002381 plasma Anatomy 0.000 description 4
238000001556 precipitation Methods 0.000 description 4
239000000047 product Substances 0.000 description 4
230000002797 proteolythic effect Effects 0.000 description 4
238000000746 purification Methods 0.000 description 4
239000011734 sodium Substances 0.000 description 4
210000001519 tissue Anatomy 0.000 description 4
HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 3
241000282414 Homo sapiens Species 0.000 description 3
241000700605 Viruses Species 0.000 description 3
239000007853 buffer solution Substances 0.000 description 3
239000008366 buffered solution Substances 0.000 description 3
238000004587 chromatography analysis Methods 0.000 description 3
235000021277 colostrum Nutrition 0.000 description 3
210000003022 colostrum Anatomy 0.000 description 3
210000001198 duodenum Anatomy 0.000 description 3
210000003743 erythrocyte Anatomy 0.000 description 3
210000003617 erythrocyte membrane Anatomy 0.000 description 3
210000003608 fece Anatomy 0.000 description 3
210000003405 ileum Anatomy 0.000 description 3
230000006872 improvement Effects 0.000 description 3
210000001630 jejunum Anatomy 0.000 description 3
239000000463 material Substances 0.000 description 3
230000000813 microbial effect Effects 0.000 description 3
230000001717 pathogenic effect Effects 0.000 description 3
230000003449 preventive effect Effects 0.000 description 3
230000002285 radioactive effect Effects 0.000 description 3
102000005962 receptors Human genes 0.000 description 3
108020003175 receptors Proteins 0.000 description 3
239000000243 solution Substances 0.000 description 3
239000002904 solvent Substances 0.000 description 3
239000000725 suspension Substances 0.000 description 3
230000003612 virological effect Effects 0.000 description 3
238000005406 washing Methods 0.000 description 3
DQJCDTNMLBYVAY-ZXXIYAEKSA-N (2S,5R,10R,13R)-16-{[(2R,3S,4R,5R)-3-{[(2S,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-(ethylamino)-6-hydroxy-2-(hydroxymethyl)oxan-4-yl]oxy}-5-(4-aminobutyl)-10-carbamoyl-2,13-dimethyl-4,7,12,15-tetraoxo-3,6,11,14-tetraazaheptadecan-1-oic acid Chemical compound NCCCC[C@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@@H](C)NC(=O)C(C)O[C@@H]1[C@@H](NCC)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DQJCDTNMLBYVAY-ZXXIYAEKSA-N 0.000 description 2
241000195940 Bryophyta Species 0.000 description 2
241000195493 Cryptophyta Species 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
241000233866 Fungi Species 0.000 description 2
102000005744 Glycoside Hydrolases Human genes 0.000 description 2
108010031186 Glycoside Hydrolases Proteins 0.000 description 2
238000012404 In vitro experiment Methods 0.000 description 2
102000004856 Lectins Human genes 0.000 description 2
108090001090 Lectins Proteins 0.000 description 2
LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
241000283973 Oryctolagus cuniculus Species 0.000 description 2
241000283903 Ovis aries Species 0.000 description 2
241000985694 Polypodiopsida Species 0.000 description 2
240000004808 Saccharomyces cerevisiae Species 0.000 description 2
102000004142 Trypsin Human genes 0.000 description 2
108090000631 Trypsin Proteins 0.000 description 2
238000001042 affinity chromatography Methods 0.000 description 2
239000003146 anticoagulant agent Substances 0.000 description 2
229940127219 anticoagulant drug Drugs 0.000 description 2
230000010065 bacterial adhesion Effects 0.000 description 2
239000013060 biological fluid Substances 0.000 description 2
239000012620 biological material Substances 0.000 description 2
210000004556 brain Anatomy 0.000 description 2
239000000872 buffer Substances 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
239000003599 detergent Substances 0.000 description 2
238000003745 diagnosis Methods 0.000 description 2
235000013601 eggs Nutrition 0.000 description 2
229940088598 enzyme Drugs 0.000 description 2
210000002919 epithelial cell Anatomy 0.000 description 2
239000012530 fluid Substances 0.000 description 2
150000004676 glycans Chemical group 0.000 description 2
230000035931 haemagglutination Effects 0.000 description 2
230000036039 immunity Effects 0.000 description 2
239000012535 impurity Substances 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
230000002779 inactivation Effects 0.000 description 2
239000012678 infectious agent Substances 0.000 description 2
210000003734 kidney Anatomy 0.000 description 2
239000002523 lectin Substances 0.000 description 2
230000000670 limiting effect Effects 0.000 description 2
238000012886 linear function Methods 0.000 description 2
210000004185 liver Anatomy 0.000 description 2
210000004072 lung Anatomy 0.000 description 2
102000006240 membrane receptors Human genes 0.000 description 2
108020004084 membrane receptors Proteins 0.000 description 2
244000000010 microbial pathogen Species 0.000 description 2
235000013336 milk Nutrition 0.000 description 2
210000004080 milk Anatomy 0.000 description 2
239000008267 milk Substances 0.000 description 2
210000000056 organ Anatomy 0.000 description 2
230000003071 parasitic effect Effects 0.000 description 2
239000002243 precursor Substances 0.000 description 2
108090000765 processed proteins & peptides Proteins 0.000 description 2
235000021309 simple sugar Nutrition 0.000 description 2
210000000813 small intestine Anatomy 0.000 description 2
238000010186 staining Methods 0.000 description 2
239000007858 starting material Substances 0.000 description 2
230000001954 sterilising effect Effects 0.000 description 2
238000004659 sterilization and disinfection Methods 0.000 description 2
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
239000012588 trypsin Substances 0.000 description 2
238000000108 ultra-filtration Methods 0.000 description 2
235000013311 vegetables Nutrition 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
108010088751 Albumins Proteins 0.000 description 1
102000009027 Albumins Human genes 0.000 description 1
RMMXTBMQSGEXHJ-UHFFFAOYSA-N Aminophenazone Chemical compound O=C1C(N(C)C)=C(C)N(C)N1C1=CC=CC=C1 RMMXTBMQSGEXHJ-UHFFFAOYSA-N 0.000 description 1
108090001008 Avidin Proteins 0.000 description 1
208000034309 Bacterial disease carrier Diseases 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
206010012742 Diarrhoea infectious Diseases 0.000 description 1
241000206602 Eukaryota Species 0.000 description 1
102000009338 Gastric Mucins Human genes 0.000 description 1
108010009066 Gastric Mucins Proteins 0.000 description 1
208000005577 Gastroenteritis Diseases 0.000 description 1
241000186660 Lactobacillus Species 0.000 description 1
108010090054 Membrane Glycoproteins Proteins 0.000 description 1
102000012750 Membrane Glycoproteins Human genes 0.000 description 1
PQMWYJDJHJQZDE-UHFFFAOYSA-M Methantheline bromide Chemical compound [Br-].C1=CC=C2C(C(=O)OCC[N+](C)(CC)CC)C3=CC=CC=C3OC2=C1 PQMWYJDJHJQZDE-UHFFFAOYSA-M 0.000 description 1
102000016943 Muramidase Human genes 0.000 description 1
108010014251 Muramidase Proteins 0.000 description 1
108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
108010058846 Ovalbumin Proteins 0.000 description 1
108010064983 Ovomucin Proteins 0.000 description 1
241001494479 Pecora Species 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
208000035992 Postmortem Changes Diseases 0.000 description 1
102000005583 Pyrin Human genes 0.000 description 1
108010059278 Pyrin Proteins 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
239000000654 additive Substances 0.000 description 1
230000004523 agglutinating effect Effects 0.000 description 1
230000004520 agglutination Effects 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
229960000212 aminophenazone Drugs 0.000 description 1
210000004381 amniotic fluid Anatomy 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
244000052616 bacterial pathogen Species 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
210000000988 bone and bone Anatomy 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
239000006143 cell culture medium Substances 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
210000001175 cerebrospinal fluid Anatomy 0.000 description 1
229960001927 cetylpyridinium chloride Drugs 0.000 description 1
YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 1
230000008859 change Effects 0.000 description 1
125000003636 chemical group Chemical group 0.000 description 1
230000007073 chemical hydrolysis Effects 0.000 description 1
238000009388 chemical precipitation Methods 0.000 description 1
238000013375 chromatographic separation Methods 0.000 description 1
238000005352 clarification Methods 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
238000004320 controlled atmosphere Methods 0.000 description 1
238000012258 culturing Methods 0.000 description 1
230000007423 decrease Effects 0.000 description 1
230000018044 dehydration Effects 0.000 description 1
238000006297 dehydration reaction Methods 0.000 description 1
238000002298 density-gradient ultracentrifugation Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
238000000502 dialysis Methods 0.000 description 1
230000029087 digestion Effects 0.000 description 1
230000005218 dilaceration Effects 0.000 description 1
238000007865 diluting Methods 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
208000001848 dysentery Diseases 0.000 description 1
238000010828 elution Methods 0.000 description 1
210000002257 embryonic structure Anatomy 0.000 description 1
230000006862 enzymatic digestion Effects 0.000 description 1
230000007071 enzymatic hydrolysis Effects 0.000 description 1
238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
238000002270 exclusion chromatography Methods 0.000 description 1
230000029142 excretion Effects 0.000 description 1
238000001125 extrusion Methods 0.000 description 1
210000001508 eye Anatomy 0.000 description 1
239000003337 fertilizer Substances 0.000 description 1
210000004700 fetal blood Anatomy 0.000 description 1
239000012894 fetal calf serum Substances 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
210000003495 flagella Anatomy 0.000 description 1
238000005194 fractionation Methods 0.000 description 1
238000007710 freezing Methods 0.000 description 1
230000008014 freezing Effects 0.000 description 1
239000003349 gelling agent Substances 0.000 description 1
238000012812 general test Methods 0.000 description 1
210000004907 gland Anatomy 0.000 description 1
230000005283 ground state Effects 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
238000000265 homogenisation Methods 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
210000001822 immobilized cell Anatomy 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
239000002054 inoculum Substances 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
238000004255 ion exchange chromatography Methods 0.000 description 1
239000003456 ion exchange resin Substances 0.000 description 1
229920003303 ion-exchange polymer Polymers 0.000 description 1
239000000644 isotonic solution Substances 0.000 description 1
230000002045 lasting effect Effects 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
231100000636 lethal dose Toxicity 0.000 description 1
239000010871 livestock manure Substances 0.000 description 1
230000001926 lymphatic effect Effects 0.000 description 1
239000004325 lysozyme Substances 0.000 description 1
229960000274 lysozyme Drugs 0.000 description 1
235000010335 lysozyme Nutrition 0.000 description 1
229920002521 macromolecule Polymers 0.000 description 1
239000003550 marker Substances 0.000 description 1
230000008774 maternal effect Effects 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
150000002772 monosaccharides Chemical class 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
229960000210 nalidixic acid Drugs 0.000 description 1
MHWLWQUZZRMNGJ-UHFFFAOYSA-N nalidixic acid Chemical compound C1=C(C)N=C2N(CC)C=C(C(O)=O)C(=O)C2=C1 MHWLWQUZZRMNGJ-UHFFFAOYSA-N 0.000 description 1
238000006386 neutralization reaction Methods 0.000 description 1
231100000957 no side effect Toxicity 0.000 description 1
WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
238000000399 optical microscopy Methods 0.000 description 1
229940092253 ovalbumin Drugs 0.000 description 1
210000000496 pancreas Anatomy 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
230000007918 pathogenicity Effects 0.000 description 1
229940049954 penicillin Drugs 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
230000002085 persistent effect Effects 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
210000002826 placenta Anatomy 0.000 description 1
238000004321 preservation Methods 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
239000002718 pyrimidine nucleoside Substances 0.000 description 1
238000011002 quantification Methods 0.000 description 1
210000003296 saliva Anatomy 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
239000000741 silica gel Substances 0.000 description 1
229910002027 silica gel Inorganic materials 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000001632 sodium acetate Substances 0.000 description 1
235000017281 sodium acetate Nutrition 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
238000002798 spectrophotometry method Methods 0.000 description 1
210000000952 spleen Anatomy 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
229960005322 streptomycin Drugs 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
210000001179 synovial fluid Anatomy 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
230000009897 systematic effect Effects 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
210000001541 thymus gland Anatomy 0.000 description 1
210000001685 thyroid gland Anatomy 0.000 description 1
108010050327 trypticase-soy broth Proteins 0.000 description 1
210000002700 urine Anatomy 0.000 description 1
238000002255 vaccination Methods 0.000 description 1
230000035899 viability Effects 0.000 description 1
239000011782 vitamin Substances 0.000 description 1
229940088594 vitamin Drugs 0.000 description 1
229930003231 vitamin Natural products 0.000 description 1
235000013343 vitamin Nutrition 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Molecular Biology (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
General Preparation And Processing Of Foods (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Plant Substances (AREA)
Peptides Or Proteins (AREA)
Steroid Compounds (AREA)
Coloring Foods And Improving Nutritive Qualities (AREA)
Compounds Of Unknown Constitution (AREA)
Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
Adhesives Or Adhesive Processes (AREA)

NO861580A 1985-04-23 1986-04-22 Fremgangsmaate for fremstilling av celleadhesjonsinhibitorer. NO861580L (no)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
FR8506124A FR2580503B1 (fr)	1985-04-23	1985-04-23	Perfectionnements apportes a la preparation des inhibiteurs de l'adhesion cellulaire, anti-adhesines ainsi obtenues et medicaments et aliments les contenant

Publications (1)

Publication Number	Publication Date
NO861580L true NO861580L (no)	1986-10-24

Family

ID=9318544

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO861580A NO861580L (no)	1985-04-23	1986-04-22	Fremgangsmaate for fremstilling av celleadhesjonsinhibitorer.

Country Status (11)

Country	Link
EP (1)	EP0201390B1 (de)
JP (1)	JPS61251623A (de)
AT (1)	ATE54255T1 (de)
AU (1)	AU594331B2 (de)
DE (1)	DE3672387D1 (de)
DK (1)	DK184886A (de)
ES (1)	ES8704349A1 (de)
FR (1)	FR2580503B1 (de)
IL (1)	IL78522A (de)
NO (1)	NO861580L (de)
NZ (1)	NZ215908A (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0380084A3 (de) *	1989-01-27	1991-03-13	The Biomembrane Institute	Methode zur Hemmung dvon Zell-Zell- und Zellsubstrat-Wechselwirkungen durch Blockierung der Kohlenhydrat-Kohlenhydrat-Wechselwirkungen
US6362003B1 (en)	1992-02-24	2002-03-26	Coulter Corporation	Hematological reference control composition containing leukocyte analogs, methods of making, and uses thereof
MY179524A (en)	2015-06-26	2020-11-10	Ferring Bv	Methods of purification and/or viral inactivation

1985
- 1985-04-23 FR FR8506124A patent/FR2580503B1/fr not_active Expired
1986
- 1986-04-16 AU AU56187/86A patent/AU594331B2/en not_active Ceased
- 1986-04-16 IL IL78522A patent/IL78522A/xx unknown
- 1986-04-17 AT AT86400831T patent/ATE54255T1/de not_active IP Right Cessation
- 1986-04-17 DE DE8686400831T patent/DE3672387D1/de not_active Expired - Fee Related
- 1986-04-17 EP EP86400831A patent/EP0201390B1/de not_active Expired - Lifetime
- 1986-04-22 NO NO861580A patent/NO861580L/no unknown
- 1986-04-22 DK DK184886A patent/DK184886A/da not_active Application Discontinuation
- 1986-04-22 NZ NZ215908A patent/NZ215908A/xx unknown
- 1986-04-23 JP JP61094374A patent/JPS61251623A/ja active Pending
- 1986-04-23 ES ES554299A patent/ES8704349A1/es not_active Expired

Also Published As

Publication number	Publication date
EP0201390B1 (de)	1990-07-04
IL78522A0 (en)	1986-08-31
FR2580503A1 (fr)	1986-10-24
AU5618786A (en)	1986-10-30
DK184886D0 (da)	1986-04-22
DE3672387D1 (de)	1990-08-09
IL78522A (en)	1991-07-18
ES8704349A1 (es)	1987-04-01
EP0201390A1 (de)	1986-11-12
FR2580503B1 (fr)	1988-02-19
JPS61251623A (ja)	1986-11-08
NZ215908A (en)	1988-08-30
DK184886A (da)	1986-10-24
AU594331B2 (en)	1990-03-08
ATE54255T1 (de)	1990-07-15
ES554299A0 (es)	1987-04-01

Publication	Publication Date	Title
Cohen et al.	1995	[24] Bacterial adhesion to and penetration of intestinal mucus in vitro
Rigney et al.	1978	Pathogenicity of Aeromonas hydrophila in red leg disease in frogs
Ruiz et al.	1982	Control of Cryptococcus neoformans in nature by biotic factors
Pramer et al.	1963	II. Nemin and the Nematode-trapping Fungi
SE508045C2 (sv)	1998-08-17	Adhesionsinhibitorer, preparat innehållande desamma och förfarande för framställning därav
SE454403B (sv)	1988-05-02	Anvendning av ett cellyteprotein med fibronektin-, fibrinogen-, kollagen-, och/eller lamininbindande egenskaper vid framstellning av sarbehandlingsmedel
Magne et al.	1991	Role of cytoskeleton and surface lectins in Giardia duodenalis attachment to Caco2 cells
Kibenge et al.	1985	Experimental reovirus infection in chickens: Observations on early viraemia and virus distribution in bone marrow, liver and enteric tissues
McLaughlin et al.	1957	Studies in marine biology. II. In vitro culture of zooxanthellae.
Allen et al.	1970	A study of the attachment phase of phagocytosis by murine macrophages
JPS58174327A (ja)	1983-10-13	治療および診断用組成物
Smorodintsev	1961	Basic mechanisms of nonspecific resistance to viruses in animals and man
NO861580L (no)	1986-10-24	Fremgangsmaate for fremstilling av celleadhesjonsinhibitorer.
Mojica et al.	2005	Biological properties of lectin from sea cucumber (Holothuria scabra Jäger)
Smith et al.	1986	A staphylococcal proteoglycan‐releasing factor
Surendra et al.	2011	Antimicrobial activity of crude venom extracts in honeybees (Apis cerana, Apis dorsata, Apis florea) tested against selected pathogens
PL156487B1 (pl)	1992-03-31	Sposób prowadzenia hodowli Treponema hyodysenteriae PL PL PL
RU2177788C2 (ru)	2002-01-10	Средство для профилактики и лечения инфекционных заболеваний и коррекции патологических состояний живого организма
RU2738671C1 (ru)	2020-12-15	Способ получения и очистки биологически активного вещества, продуцируемого бифидобактериями
Feinberg	1953	A method for the bulk growth of a parasitic protozoan
US5846789A (en)	1998-12-08	Process for preparing nontoxic lipopolysaccharides from acidiphilium species
Al-Azawy et al.	2017	Study the inhibitory effect of purified lipopolysaccharide extracted from Proteus mirabilis on E. coli O157 H7 isolate from diarrheal infected animals
Zagumennov et al.	2021	Dynamics of immunological parameters of blood serum of calves in the treatment of keratoconjunctivitis using the drug ligfol.
Gao et al.	2020	Identification and characterization of a novel mannose-binding C-type lectin (PjLec2) in shrimp Penaeus japonicus
CN115992116B (zh)	2024-04-12	一种多功能奶牛溶菌酶及其制备方法和应用